Article
Pembrolizumab induced hyperpigmentation in a patient with lung adenocarcinoma: a case report
2021-07-05
Abstract excerpt
Pembrolizumab is more widespread use clinically with Pembrolizumab being recommended as a first-line therapy for advanced NSCLC. At the same time, some new adverse reactions have also been discovered, including hyperpigmentation. We hereby present a 77-year-old Chinese female with primary bronchial lung cancer. Genetic testing showed negative for EGFR and ALK. Immunohistochemical analysis showed tumor proportion s...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 78a2f0ef-46b9-54b3-b75f-00d0ab8c349f
- DOI
- 10.22541/au.162546820.05792179/v1
